Chronic back pain is one of the most actively researched areas in regenerative medicine.
Persistent low back pain, sciatica, and disc-related concerns are among the most common reasons adults look into regenerative options, and they are also among the most studied. Multiple randomized controlled trials have examined intradiscal cell therapy for degenerative disc disease, several of them multi-site and placebo-controlled with follow-up out to three years.
This page covers what that research has found, what a proper candidacy review examines, and what to ask before you commit to anything.
Aurenza does not claim that regenerative medicine treats or reverses back or spinal conditions.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
Chronic low back pain from degenerative disc disease is one of the most rigorously studied applications in all of regenerative medicine, and the trials here are the kind that survive scrutiny: randomized, placebo-controlled, multi-site, and long.
In a 36-month randomized, placebo-controlled trial published in The Spine Journal (2021), a single intradiscal injection of allogeneic mesenchymal precursor cells was studied in 100 patients with chronic low back pain and moderate degenerative disc disease across 13 clinical sites in the United States and Australia. The authors concluded the approach could be a safe, effective, durable, and minimally invasive option for this patient group, with adverse events not significantly different from controls. A second 36-month randomized, concurrent-controlled study of the same cell platform00164-0/abstract), published in The Spine Journal in 2025, again reported significant improvements in pain and function at multiple timepoints.
Europe ran its own version of the question. The RESPINE trial, published in Annals of the Rheumatic Diseases (2024), was a prospective, multicentre, randomised, placebo-controlled study of a single intradiscal injection of 20 million allogeneic bone marrow stromal cells, conducted between 2018 and 2022 with pain and disability tracked out to 24 months.
Zoom out from single trials and the pooled picture points the same direction. A systematic review and meta-analysis of randomized controlled trials in Stem Cells International found MSC therapy for degenerative disc disease significantly decreased both pain scores and Oswestry Disability Index scores, with more patients reaching clinically meaningful improvement thresholds, and a 2023 meta-analysis in Frontiers in Bioengineering and Biotechnology reached the same conclusion on discogenic pain. The platform studied in the U.S. trials is registered at ClinicalTrials.gov under NCT02412735, which means every claim above can be traced to a public record.
The Honest Line
Here is what that research does not say, because you deserve both halves. Recent systematic reviews of the clinical literature are consistent: trials show statistically significant improvements in pain and disability, while clear imaging proof of structural disc repair has not been established, and reviewers note methodological weaknesses across parts of the evidence base. No study shows a guarantee that it works every time, or that it will work for you. The trials produced their results in patients with confirmed discogenic pain selected against strict criteria, and that selection is a large part of why the results look the way they do.
Why This Is Exactly Where a Candidacy Review Comes In
Back pain is also the area of medicine where imaging and symptoms disagree most often, so establishing that your pain actually comes from the structure a protocol would target is the single most valuable step in the entire process. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
- Your imaging history, and whether the findings plausibly connect to where and when you actually hurt.
- Your diagnosis, including whether it is current and adequately worked up.
- Prior procedures, since previous surgery, fusion, or hardware changes both the anatomy and the calculus.
- Your pain pattern, which is frequently more informative than the scan.
- Functional limitations and activity goals, which define what a meaningful result would look like for you.
- Your bloodwork and medical records, because systemic inflammation and metabolic health affect the environment any approach is placed into.
- Your case is then reviewed by a physician panel, with specialists brought in where the case calls for it.
What to Ask Any Provider
What specifically do you believe is generating my pain, and what is that based on? Does my presentation match the patient population in the published trials? What is being administered, from what source, and what is the verified cell count? Which studies are you relying on, and were they conducted with a comparable product? What would make me a poor candidate? What are the realistic possibilities, including no change?
A provider who welcomes those questions is behaving well. One who deflects is telling you something.
The Honest Limits
Individual results cannot be predicted or guaranteed. These applications are not FDA approved for these conditions, and the procedure takes place in Mexico under COFEPRIS regulation. Continue care with your existing providers, and seek urgent evaluation for progressive weakness, numbness, or bowel and bladder changes.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.